Ligand Pharmaceuticals
LGND
293.26
-3.68
-1.24%
Ligand Pharmaceuticals
US · LGND
#1920 by market cap
Listed 1970
293.26
-3.68
-1.24%
Live - 5344 symbols - heartbeat 567s ago
· 2026-10-08 07:58
Pre-market
293.26
0.00%
After-hours
293.26
0.00%
- Market cap
- 5.85B
- P/E (TTM)i
- 30.20
- P/Bi
- 6.04
- EPSi
- 6.13
- Div yieldi
- 0.00%
- 52W posi
- 78%
Reader sentiment
Are you bullish or bearish on LGND?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 9 analysts
Buy
Avg price target
356.29 +21.5%
Price target rangecurrent 293.26
Low326.00
Avg356.29
High397.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-25 | Barclays | -- | BUY | 345.00 |
| 2026-09-24 | Craig-Hallum | -- | BUY | -- |
| 2026-09-24 | H.C. Wainwright | -- | BUY | 358.00 |
| 2026-09-23 | Citi | -- | BUY | 397.00 |
| 2026-09-22 | Craig-Hallum | -- | BUY | -- |
| 2026-09-22 | BofA Securities | -- | BUY | 388.00 |
| 2026-09-22 | Stifel | -- | BUY | -- |
| 2026-09-22 | Citi | -- | BUY | 397.00 |
| 2026-09-21 | H.C. Wainwright | -- | BUY | 358.00 |
| 2026-08-14 | Stifel | -- | BUY | 332.00 |
| 2026-08-12 | Citi | -- | BUY | 390.00 |
| 2026-08-09 | RBC Capital | -- | BUY | 345.00 |
| 2026-08-07 | Craig-Hallum | -- | BUY | 370.00 |
| 2026-08-07 | BofA Securities | -- | BUY | -- |
| 2026-08-07 | H.C. Wainwright | -- | BUY | 358.00 |
| 2026-08-07 | Oppenheimer | -- | BUY | 326.00 |
| 2026-08-06 | H.C. Wainwright | -- | BUY | 358.00 |
| 2026-08-06 | RBC Capital | -- | BUY | 345.00 |
| 2026-08-03 | Oppenheimer | -- | BUY | 326.00 |
| 2026-07-22 | BofA Securities | -- | BUY | 388.00 |
| 2026-07-21 | Citi | -- | BUY | 387.00 |
| 2026-07-16 | StoneX | -- | BUY | 335.00 |
| 2026-07-14 | RBC Capital | -- | BUY | 340.00 |
| 2026-07-13 | Craig-Hallum | -- | BUY | -- |
| 2026-07-09 | BofA Securities | -- | BUY | 388.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-06 | -- | ±7.03% | -0.80% (in line) |
| 2026/Q1 | 2026-05-07 | -- | ±6.32% | -9.55% (beat) |
| 2025/Q4 | 2026-02-26 | -- | ±8.12% | +2.50% (in line) |
| 2025/Q3 | 2025-11-06 | -- | ±5.73% | +9.37% (beat) |
| 2025/Q2 | 2025-08-07 | -- | ±7.16% | +2.75% (in line) |
| 2025/Q1 | 2025-05-08 | -- | ±11.73% | -2.94% (in line) |
| 2024/Q4 | 2025-02-27 | -- | ±10.17% | +0.57% (in line) |
| 2024/Q3 | 2024-11-07 | -- | ±9.17% | +11.12% (beat) |
| 2024/Q2 | 2024-08-06 | After close | ±9.54% | -5.78% (in line) |
| 2024/Q1 | 2024-05-07 | After close | ±9.58% | +9.75% (beat) |
| 2023/Q4 | 2024-02-27 | -- | ±8.17% | +19.86% (beat) |
| 2023/Q3 | 2023-11-08 | After close | ±11.97% | +4.61% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:58:31 · For reference only, not investment advice and not tailored to your situation.